跳至主要内容
临床试验/NCT02678169
NCT02678169已完成不适用

A Prospective, Multicenter, Observational, Single-arm European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke

Penumbra Inc.1 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2016年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Penumbra Inc.
入组人数
204
试验地点
1
主要终点
Angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by a TICI 2b or 3 score.

研究概览

简要总结

Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe. Consecutive patients presenting within 6 hours from symptom onset with an acute ischemic stroke (within the internal carotid artery and internal carotid terminus, middle cerebral - M1/M2 segments) due to anterior circulation large vessel occlusion (LVO) will be treated using the ADAPT technique with thrombo-aspiration as first intention and site routine practice.

详细描述

Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe. Consecutive patients presenting within 6 hours from symptom onset with an acute ischemic stroke (within the internal carotid artery and internal carotid terminus, middle cerebral - M1/M2 segments) due to anterior circulation large vessel occlusion (LVO) will be treated using the ADAPT technique with thrombo-aspiration as first intention and site routine practice.

The follow-up visit will occur 24 hours, 7-10 days or discharge, 30 days and 90 days post-procedure and will review patient's functional outcome, quality of life, and adverse events.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • General inclusion criteria:
  • From 18 years of age
  • Present with symptoms consistent with an acute ischemic stroke within 6 hours of stroke symptom onset
  • Arterial occlusion of the distal intracranial carotid artery (ICA and ICA terminus) or middle cerebral artery (M1/M2)
  • National Institute of Health Stroke Scale (NIHSS) ≥ 2
  • Signed Informed Consent Form.
  • Imaging inclusion criteria:
  • CT ASPECT score from 6 to 10 (>6) or according to MR DWI ASPECT score from 5 to 10 (>5).

排除标准

  • General exclusion criteria:
  • Associated myocardial infarction or severe infection (endocarditis or sepsis)
  • Laboratory evidence of coagulation abnormalities, with an International Normalized Ratio (INR) of > 3.0 or platelets count < 40 x109/L or APTT > 50 sec
  • Uncontrolled hypertension (defined as systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg)
  • Baseline glucose < 2.7 or > 22.2 mmol/L
  • Pre-stroke mRS score > 2
  • Seizure at the onset of stroke
  • Arterial tortuosity that would prevent the device from reaching the target vessel
  • Time of stroke symptoms onset unknown
  • Life expectancy less than 90 days prior to stroke onset
  • Females who are pregnant or lactating
  • Known serious sensitivity to radiographic contrast media.
  • Imaging exclusion criteria:
  • CT/MRI evidence of the following conditions at screening:
  • Significant mass effect with midline shift
  • Evidence of intracranial hemorrhage (ICH), aneurysm, or arteriovenous malformation (AVM)
  • Angiographic evidence of tandem extracranial occlusion or an arterial stenosis proximal to the occlusion that requires treatment prior to thrombus removal. Moderate stenosis not requiring treatment is not an exclusion criterion.
  • Angiographic evidence of preexisting arterial injury, such as carotid dissection, complete cervical carotid occlusion, or vasculitis.

结局指标

主要结局

Angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by a TICI 2b or 3 score.

时间窗: Immediate post-procedure

Functional patient outcome at 90 days post-procedure as defined by a modified Rankin Score (mRS) 0-2.

时间窗: 90 days post-procedure

次要结局

  • Incidence of device and procedure related Serious Adverse Events (SAEs) at 24 hours and 30 days from stroke treatment(24 hours and 30 days from stroke treatment)
  • All causes of mortality and morbidity at 90 days(90 days)
  • Occurrence of embolization in previously uninvolved (or new) territories (ENT) as seen on the final control angiogram at the end of procedure(At the end of interventional surgical procedure)
  • Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours(24 hours)
  • Occurrence of vessel damages at the end of the ADAPT procedure.(At the end of the interventional surgical procedure)
  • NIHSS score at 7-10 days post-procedure.(7-10 days post-procedure)
  • Times to revascularization(From symptom onset to various times during the interventional surgical procedure)
  • Quality of Life: EQ-5D 3L score at 90 days compared to the one at 7-10 days post-procedure.(90 days)
  • Heath Economics: Total duration of hospitalization with related healthcare resources(Average time frame 3-7 days.)

研究者

发起方
Penumbra Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验